Articles tagged with Lung Cancer
Scientists have pinpointed a weakness in lung cancer's defenses by uncovering an enzyme that boosts cancer cell metabolism to fuel growth. Researchers identified GUK1 as a metabolic enzyme that plays a crucial role in ALK-positive cancers, suggesting it may be a target for new therapies.
The Micro Immune Response On chip (MIRO) replicates tumours and their environment, allowing researchers to study the efficacy of immunotherapy treatments. This technology has been tested with breast cancer samples and shows promise in understanding how the immune system interacts with tumours.
A new genetic mutation, RUFY1-RET fusion, was discovered in a patient with stage IV CD-74-ROS1 fusion NSCLC who developed resistance to lorlatinib. The finding highlights the importance of ongoing genetic testing to guide therapy decisions.
A new low-cost, fast response sensor has been developed to detect lung cancer biomarkers, enabling early diagnosis and improved patient outcomes. The technology can identify patients at higher risk of lung cancer and tailor treatments for those already diagnosed.
Researchers developed a computer model called MANAscore to identify tumor-fighting immune cells in lung cancer patients treated with immune checkpoint inhibitors. The three-gene model helped find differences associated with patient response to immunotherapy, including the presence of stem-like memory T cells.
Researchers at H. Lee Moffitt Cancer Center discovered a biomarker that can predict which lung cancer patients with KRASG12C mutation are most likely to benefit from targeted treatments. The study found that tumors with higher levels of RAS-RAF protein interaction respond better to KRASG12C inhibitors.
The addition of da Vinci 5 robotic surgical systems at Huntsman Cancer Institute offers enhanced precision and control during minimally invasive surgeries. The system's advanced technology enables complex procedures to be performed through small incisions, reducing hospital stays and accelerating recovery times for patients.
The study analyzed 63 tumor samples from 10 common malignancies, revealing how malignant cells specialize in growing tumors and non-cancer cells contribute to the immune system's suppression. The findings suggest a hierarchical structure of tumors with specific hallmark expression patterns.
A pooled data analysis found that cancer chemotherapy is linked to persistent severe peripheral nerve pain for around 4 in every 10 patients, with platinum-based drugs and taxanes associated with the highest rates of painful neuropathy. The study analyzed data from 77 eligible studies involving 10,962 participants from 28 countries.
Research presented at the 2025 STS Annual Meeting reveals that anatomic lung resections such as lobectomy and segmentectomy are associated with improved long-term survival compared to wedge resection for stage 1A NSCLC. Lobectomy offered the highest survival rates, with a 71.9% 5-year OS and 44.8% 10-year OS.
The Chris Chang Lab develops a copper-detection tool to uncover how copper regulates cell growth in lung cancer. The probe identifies cells with elevated copper levels and reveals a connection between copper and the antioxidant response mediated by NRF2.
A new deep learning model has been developed to detect and segment lung tumors on CT scans with high accuracy. The model achieved 92% sensitivity and 82% specificity in detecting lung tumors, outperforming physician-delineated volumes in some cases. However, further research is needed to improve the model's performance for larger tumors.
The FDA has revoked authorization for the use of Red Dye 3 in food and ingested drugs, citing studies linking it to cancer in laboratory male rats. This decision is an important step forward in addressing modifiable risk factors that have the potential to reduce cancer risk.
A recent study found that U.S. soldiers are 10 times more likely to use nicotine pouches, which can cause serious health issues, compared to the general population. The study analyzed anonymous responses from 1,957 soldiers and found that 23.8% reported using nicotine pouches in the previous 30 days.
A new test detecting tiny fragments of DNA in blood plasma can predict lung cancer relapse and overall survival. Patients with low levels of tumor DNA before surgery have improved survival rates, while those with high levels are more likely to relapse.
A cross-sectional study found that American Indian/Alaska Native populations are significantly farther away from lung cancer screening centers than non-Hispanic White populations. The researchers recommend increasing access to lung cancer services through mobile units and imaging locations to address these disparities.
A new study found that Medicare Advantage patients with colorectal cancer are six percentage points less likely to receive a cancer drug compared to those on Traditional Medicare. For non-small cell lung cancer, the pattern was not as clear due to limited low-cost treatment options.
A new test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors. This could help doctors make more informed treatment decisions for people with stage 1 lung cancer, potentially improving patient outcomes.
A new study found that while lung cancer deaths decreased globally from 1990 to 2019, mortality linked to tobacco use and air pollution increased. Tobacco remains the leading cause of death, accounting for 66% of TBL cancer deaths in 2019, while particulate matter pollution is a growing concern.
Researchers developed a novel inhalable therapeutic delivery system for lung cancer using mucoadhesive protein nanoparticles inspired by marine mussels. The approach leverages the adhesive properties of mussel proteins to enable selective payload release and minimize adverse effects.
Researchers have developed a way to detect circulating tumor cells in the bloodstream using biolasers, which can provide valuable information about the DNA organization inside cancer cells. The technique has been successfully tested on pancreatic and lung cancer patients, showing high accuracy rates of up to 99%.
The study found that high levels of aspartate in the lungs are associated with aggressive lung metastases, triggered by an alternative translation program driven by aspartate signaling. This discovery suggests a common feature of cancer cells growing in the lung and provides a potential target for new therapeutic interventions.
Researchers discovered that blocking cell cycle inhibitor p21 prevents lung cancer cells from entering a quiescent state, allowing for more cancer cell death before and after chemotherapy. This leads to reduced cancer relapse rates, improving patient outcomes.
A review of 3,000 studies suggests microplastics in the air may cause serious health problems, including colon cancer, poor lung function, and infertility. The tiny plastic particles are believed to contribute to chronic pulmonary inflammation, increasing the risk of lung cancer.
A new diagnostic test uses a unique molecular 'finger print' to detect different types of cancer, with near-perfect accuracy, and could lead to earlier detection and improved patient outcomes. The test targets ribosomal RNA molecules, which are modified differently in healthy and diseased tissues.
Researchers combine a precision cancer drug with an antibody and radiation therapy to eliminate tumors without causing side effects. The approach uses the cancer drug as a molecular flag for cancerous cells, allowing immune cells to target them. This method has shown promise in eliminating lung cancer in mice with minimal side effects.
The study found that smokers with myelodysplastic syndromes (MDS) or precursor conditions had elevated levels of genetic mutations linked to the disease. Heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
A national lung cancer screening program is proposed to reduce deaths and improve survival rates for Australian patients. The Flinders University study found that screening individuals aged 50-70 every two years would be cost-effective and add significant years of healthy life.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.
The PoweRD 2 Cure ALK+ Lung Cancer TeamLab aims to identify and exploit vulnerabilities of leftover cancer cells to prevent recurrence. By combining new strategies, structures, and thinking from across disciplines, researchers hope to develop treatment strategies that leave no cancer cells alive.
The global lifetime risk of lung cancer is 3.49%, with high-risk countries like French New Caledonia and Canada, while low-HDI countries have lower risks due to shorter lifespans and limited resources. After 40, the risk drastically increases, but residual risk decreases with age.
Researchers found that as cells age, they lose regenerative capacity and become less susceptible to cancer. The study's findings suggest that therapies targeting ferroptosis may be less effective in older patients.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
A new study reveals that lung cancer screening CTs can detect coronary artery disease in 83% of cases, with high levels found in 30%. This finding highlights the potential benefits of lung cancer screening for identifying and managing cardiovascular risk factors.
A series of five papers highlights critical public health challenges related to cancer control in eight SAARC countries and the Rohingya refugee population in Bangladesh. The studies identify barriers contributing to significant disparities in cancer outcomes and actionable solutions to address these challenges.
This study compares the pharmacokinetics of aumolertinib, osimertinib, and gefitinib in mouse models and NSCLC patients. Aumolertinib exhibits better pharmacokinetic profiles, with higher concentrations in plasma and tissues, making it a promising candidate for EGFR mutation-positive NSCLC treatment.
The IASLC and LCRF have awarded a $2.5 million team science grant to Dr. David Barbie's research team to develop an immune-based approach to target drug-resistant lung cancer cells. The project aims to harness the body's immune system to eliminate persister cells, which contribute to disease progression.
Sylvester researchers will present over 130 studies at ASH 2024, addressing disparities in gastric cancer. Frank J. Penedo's research highlights worse outcomes for patients with unmet supportive needs, while Shria Kumar's work seeks answers for disparities in gastric cancer among specific minorities.
Scientists use machine learning-based classifiers to differentiate lung cancer and noncancer based on urinary miRNA ensembles. The study reveals high specificity and sensitivity in detecting early-stage lung cancer, offering new hope for improved patient outcomes.
A study by Niigata University found that AI analysis of PET/CT images can predict the occurrence of interstitial lung disease, a serious side effect of immunotherapy. Patients with high inflammation in non-cancerous lungs are at a higher risk of developing this condition.
Researchers successfully delivered anti-cancer ASO molecules to lung tumor sites using human red blood cells, demonstrating potent anti-cancer effects against NSCLC. The approach utilizes EGFR-targeting moieties to home in on cancerous cells, offering a potentially powerful treatment modality for personalized cancer medicine.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
A new study published in The British Journal of Cancer found that whole genome sequencing can help identify treatment recommendations for cancer patients. The study evaluated the regional implementation of the 100,000 Genomes Project and found that different types of cancer were associated with varying rates of recommended actions.
Researchers have developed ultrasensitive sensors that can detect isoprene levels in the parts-per-billion range, a decline of which can indicate lung cancer. The sensors, made with indium oxide-based nanoflakes, showed promise in distinguishing lung cancer patients from healthy individuals.
A joint research team at Korea University College of Medicine announced the world's first comparative results of single-port robotic thymectomy, showing a lower conversion rate to multi-port surgery and shorter hospital stays. The study demonstrated that single-port robotic thymectomy is a safer alternative to traditional VATS thymectomy.
Researchers analyzed tumor samples from 64 SCLC patients, identifying promising results for biomarkers DLL3 and TTF-1. These biomarkers showed potential as targets for therapies like Tarlatamab and improved survival rates in patients with TTF-1-positive tumors.
A low-dose CT scan can pick up on early-stage lung cancers, which can often be completely removed with surgery. However, less than a fifth of those eligible for the test are getting it, highlighting awareness and communication gaps.
A new initiative, CAL-PALS, aims to expand access to life-saving lung cancer screening for marginalized groups in Los Angeles County. The program will engage physicians and staff to create system-level changes increasing access to high-quality services.
Researchers have developed a large-scale drug screening technique that tracks drug targets inside cells, allowing for the identification of potential new drugs. The technology screens candidate drugs 100 times faster than standard manual techniques, enabling the discovery of previously unknown drugs.
Researchers have discovered a therapeutic approach that shows promise in preclinical models for treating cancers driven by RAS mutations. The study found that tri-complex inhibitors can restore the normal functioning of mutated RAS proteins, aiming to correct the defect that drives cancer growth.
A recent study found that endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) provided sufficient tissue for identifying actionable genetic aberrations in patients with advanced non-small cell lung cancer. Liquid biopsy samples were also analyzed and compared to EBUS-TBNA results, demonstrating similar findings.
A new lung cancer screening initiative in Central Texas has successfully increased screenings among low-income and minority populations. The program's patient-centered approach, including bilingual support and no-cost screenings, resulted in an 83% completion rate of low-dose CT scans among eligible patients.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers have developed a 'mini-protein' that targets cancer cells expressing Nectin-4, allowing for direct delivery of radiation to tumours. The treatment shows promise in targeting multiple types of cancers and has the potential to be safe for repeated administrations.
A national report reveals nearly 18% of Canadian homes have radon levels above 200 Bq/m³, increasing lung cancer risk. Canadians are among the most highly exposed to radon, highlighting the need for urgent action to address this public health concern.
Researchers found that physically fitter patients with metastatic lung cancer live longer and respond better to chemotherapy. The study identified biomarkers in blood plasma that can indicate which patients are most likely to respond to treatment.
Researchers reported a complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer patient with brain metastases. The patient achieved overall survival of 87 months and progression-free survival of 73 months after treatment sequencing.
A study at the University of Texas M.D. Anderson Cancer Center found that adding CTLA-4 immune checkpoint inhibitors to durvalumab and chemotherapy improved overall response rates, progression-free survival, and overall survival for patients with metastatic non-squamous non-small cell lung cancer harboring STK11 and/or KEAP1 mutations.
Researchers identified AM-101 as a potential new way to enhance radiation therapy for patients with lung cancer that has spread to the brain. The drug's ability to activate GABA(A) receptors increases autophagy in lung cancer cells, making them more sensitive to radiation treatment.
Researchers developed a microchip that captures exosomes from blood plasma to identify signs of lung cancer, achieving 10x faster detection and 14x greater sensitivity. The chip uses twisted gold nanoparticles to distinguish between healthy patients and those with lung cancer.